Form 6-K ASTRAZENECA PLC For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
AstraZeneca (AZN) Tops Q2 EPS by 21c; Boosts Outlook
July 31, 2014 8:53 AM EDTAstraZeneca (NYSE: AZN) reported Q2 EPS of $1.30, $0.21 better than the analyst estimate of $1.09. Revenue for the quarter came in at $6.45 billion versus the consensus estimate of $6.24 billion.
The Company increases its revenue and Core EPS guidance for the full year:
Revenue is expected to be in line with 2013 at CER, an increase on our previous guidance of low-to-mid single digit percentage decline. Core EPS... More